Back to search

Article

Investigating the Effects of Semaglutide in Early Alzheimer’s Disease Using Single-cell Transcriptomics and Proteomics – Rationale and Design (P12-3.017)

2025-04-07

Abstract excerpt

The aim of this exploratory phase 3 study is to investigate the effect of once-weekly subcutaneous semaglutide on central (cerebrospinal fluid [CSF]) and peripheral (blood) inflammation using single-cell transcriptomics (i.e. gene expression in individual cells) to expand the molecular understanding of semaglutide and Alzheimer’s disease (AD).

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
974af8ff-4dfa-5deb-a957-05bfd8b2cf86
DOI
10.1212/wnl.0000000000211162
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 11 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Investigating the Effects of Semaglutide in Early Alzheimer’s Disease Using Single-cell Transcriptomics and Proteomics – Rationale and Design (P12-3.017)DOI 10.1212/wnl.0000000000211162
CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and mild-to-moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signaturesSemantic proximity
A single-cell atlas of the human brain in Alzheimer’s disease and its implications for personalized drug repositioningSemantic proximity
An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimer’s diseaseSemantic proximity
An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's diseaseSemantic proximity
Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease PatientsSemantic proximity
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's diseaseSemantic proximity
A stem cell secretome delays functional decline and supresses inflammation in two distinct models of neurodegenerationSemantic proximity
A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial of Intracisternal Engineered Autologous Exosomes (NV-101) to Restore Neuronal Proteostasis in Early Alzheimer’s Disease: The RESTORE ProtocolSemantic proximity
Semaglutide Attenuates Neuroinflammation in MiceSemantic proximity
A preclinical and phase I clinical study of ex vivo-expanded amyloid beta-specific human regulatory T cells in Alzheimer’s diseaseSemantic proximity
Protein aggregation inhibitors induce divergent transcriptional responses in a cellular model of ɑ-synuclein seeded aggregationSemantic proximity
Select a neighboring publication to make it the new centre.